The impact of chemotherapy shortages on COG and local clinical trials: A report from the Children's Oncology Group
Pediatric Blood & Cancer2015Vol. 62(6), pp. 940–944
Citations Over TimeTop 10% of 2015 papers
Abstract
Chemotherapy shortages remain widespread across institutions, hinder clinical trials, and may contribute to adverse events in children with cancer. The increased frequency of chemotherapy shortages reported by pharmacists suggests that pharmacist efforts may mitigate negative impact chemotherapy shortages. Over half of pediatric institutions are implementing recommendations to address shortages, such as cross-institutional collaboration and center-level guidelines.
Related Papers
- → Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals(2020)29 cited
- → A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia(2008)50 cited
- → Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review(2022)14 cited
- → Daunorubicin & Cytarabine Liposome (Vyxeos™)(2018)16 cited
- → Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin(2009)6 cited